Tag: ipilimumab

BMS’ Opdivo plus Yervoy combo gets EC approval for metastatic NSCLC

pharmanewsdaily- November 8, 2020

Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small ... Read More

FDA approves BMS’ Opdivo, Yervoy combo for malignant pleural mesothelioma

pharmanewsdaily- October 4, 2020

Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line ... Read More